Genetic Technologies Limited (GENE) Comparison with companies in other sectors?

Genetic Technologies Limited has a share price of 145.42M. You can analyze Genetic Technologies Limited (GENE) competitors across different market sectors through stock heatmaps.

What are GENE's NET and operating margins?

Genetic Technologies Limited (GENE) operating margin is around -0.99, and net profit margin is approximately -1.37 as of the latest reports.

In what way does GENE's earnings per share (EPS) trend reflect its financial momentum?

Genetic Technologies Limited (GENE) EPS is -0.02 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Genetic Technologies Limited is -38.25, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Genetic Technologies Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Genetic Technologies Limited like P/E which is -0.48, P/B which is 3.16, and PEG which is -0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

Genetic Technologies Limited

GENE•NASDAQ

Healthcare

Medical - Diagnostics & Research

$0.77

$0.00(0.00%)

Fundamental Analysis of Genetic Technologies Limited (GENE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.02

P/E Ratio

-38.25

ROE

-3.62%

Net Margin

-1.37%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$111.24M

Shares OutstandingTotal number of shares issued

$145.42M

Book Value/ShareNet worth per share

$0.01

Revenue/ShareAnnual revenue per share

$0.06

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.02

Net MarginNet income as percentage of revenue

-137.21%

Operating MarginOperating income as percentage of revenue

-98.57%

ROEReturn on shareholders' equity

-361.83%

ROAReturn on total assets

-194.25%

ROCEReturn on capital employed

-433.60%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.06

Cash/ShareCash and equivalents per share

$0.007

FCF YieldFree cash flow as percentage of market cap

-5.65%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for GENEFinancial Ratios Analysis details for GENE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for GENESector Benchmarking details for GENE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Genetic Technologies Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Genetic Technologies Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Genetic Technologies Limited's unique business strengths and challenges.

Key Financial Metrics for Genetic Technologies Limited

For Genetic Technologies Limited, essential financial indicators include EPS -0.02, PE -38.25, and ROE -3.62. These key ratios reveal insights into Genetic Technologies Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Genetic Technologies Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Genetic Technologies Limited

Metrics like Net Margin -137.21% and ROA -194.25% shed light on how well Genetic Technologies Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Genetic Technologies Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Genetic Technologies Limited

Using ratios such as P/B Ratio 3.16 and PEG Ratio -0.01, investors can assess whether Genetic Technologies Limited is appropriately valued based on its financials and growth potential. These figures, combined with Genetic Technologies Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Genetic Technologies Limited

Financial health indicators, such as Debt/Equity Ratio 0.48 and Cash Flow $-0.06, provide a snapshot of Genetic Technologies Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Genetic Technologies Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Genetic Technologies Limited

Investing in Genetic Technologies Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Genetic Technologies Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;